As CAR T-cell therapies have gained approvals in relapsed/refractory mantle cell lymphoma (MCL) and follicular lymphoma (FL) patient populations, there is continued interest in the optimal administration of this treatment option. CAR T-cell therapy is typically administered in the hospital setting, but as the therapy continues to become more widely used in clinical practice, there is renewed interest in using the therapy in the ambulatory setting. Therefore, a real-world analysis exploring the outcomes of inpatient and outpatient administration of CAR T-cell therapy in patients with MCL and FL was performed. In the study, inpatient infusion was associated with a higher comorbidity burden and increased likelihood of adverse events (AEs) in patients with PML who received CAR T-cell therapy, but not in those with MCL. However, in the real-world MCL (n = 151) and FL (n = 267) populations, the median time from leukapheresis to CAR T-cell infusion was similar for MCL and FL in both infusion settings between 25 and 27 days. AEs were observed in 68% and 59% of MCL and PML patients, respectively, within 30 days of infusion. A total of 20% to 25% of patients received CAR T-cell therapy infusions on an outpatient basis.
